GV-150013

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C33H34N4O3
Molecular Weight	534.6481
Optical Activity	( - )
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C(N[C@@H]1C(=O)N(CC23CC4CC(CC(C4)C2)C3)C5=CC=CC=C5N(C6=CC=CC=C6)C1=O)NC7=CC=CC=C7

InChI

InChIKey=RZERRLOTRSJIAW-NEPGVILWSA-N

InChI=1S/C33H34N4O3/c38-30-29(35-32(40)34-25-9-3-1-4-10-25)31(39)37(26-11-5-2-6-12-26)28-14-8-7-13-27(28)36(30)21-33-18-22-15-23(19-33)17-24(16-22)20-33/h1-14,22-24,29H,15-21H2,(H2,34,35,40)/t22?,23?,24?,29-,33?/m1/s1

HIDE SMILES / InChI

Molecular Formula	C33H34N4O3
Molecular Weight	534.6481
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

PubMed

Title	Date	PubMed
The role of cholecystokinin (CCK), CCK-A or CCK-B receptor antagonists in the spontaneous preference for drugs of abuse (alcohol or cocaine) in naive rats.	1998 Oct	9922984
Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists.	2000 Oct 5	11020274

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:15:33 GMT 2025` Edited by `admin` on `Mon Mar 31 18:15:33 GMT 2025`
Record UNII	WSFVPEEMNO
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Urea, N-phenyl-N?-[2,3,4,5-tetrahydro-2,4-dioxo-1-phenyl-5-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-1H-1,5-benzodiazepin-3-yl]-, (R)-

Preferred Name

English

GV-150013

Code

English

Urea, N-phenyl-N?-[(3R)-2,3,4,5-tetrahydro-2,4-dioxo-1-phenyl-5-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-1H-1,5-benzodiazepin-3-yl]-

Systematic Name

English

N-Phenyl-N?-[(3R)-2,3,4,5-tetrahydro-2,4-dioxo-1-phenyl-5-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-1H-1,5-benzodiazepin-3-yl]urea (-)

Systematic Name

English

Code System Code Type Description

CAS

167355-22-8

Created by admin on Mon Mar 31 18:15:33 GMT 2025 , Edited by admin on Mon Mar 31 18:15:33 GMT 2025

PRIMARY

PUBCHEM

5311147

Created by admin on Mon Mar 31 18:15:33 GMT 2025 , Edited by admin on Mon Mar 31 18:15:33 GMT 2025

PRIMARY

FDA UNII

WSFVPEEMNO

Created by admin on Mon Mar 31 18:15:33 GMT 2025 , Edited by admin on Mon Mar 31 18:15:33 GMT 2025

PRIMARY

Related Record Type Details


					B3NY85624O

CHOLECYSTOKININ-2 RECEPTOR

TARGET -> INHIBITOR

Amount:

Related Record Type Details


					WSFVPEEMNO

GV-150013

ACTIVE MOIETY

Comments:

Phase II clinical trials for anxiety and sleep disorders.

Amount: